BANK VONTOBEL/PUT/NOVO NORDISK ADR B/110/0.1/20.09.24

BANK VONTOBEL/PUT/NOVO NORDISK ADR B/110/0.1/20.09.24 Share Price

DE000VM8D3U6

Market Closed - Boerse Frankfurt Warrants 11:23:04 05/07/2024 pm IST
0.057 ^EUR	-8.06%

Current month	+32.56%
1 month	-26.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart BANK VONTOBEL/PUT/NOVO NORDISK ADR B/110/0.1/20.09.24

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?	07/02	PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?	01/02	PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?	17/01	PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog?	11/01	PR

More news

Quotes 5-day view

Date	Price	Change
05/24/05	0.057	-8.06%
04/24/04	0.062	-16.22%
03/24/03	0.074	+45.10%
02/24/02	0.051	+64.52%
01/24/01	0.031	-27.91%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 11:23 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
WKN	VM8D3U
ISIN	DE000VM8D3U6
Date issued	11/01/2024
Strike	110 $
Maturity	20/09/2024 (76 Days)
Parity	10 : 1
Emission price	0.97 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.17 €
Lowest since issue	0.031 €
Delta	-0.06x
Omega	12.07
Premium	23.28x
Gearing	212.03x
Moneyness	0.7719
Difference Strike	-32.37 $
Difference Strike %	-29.43%
Spread	0.01 €
Spread %	14.93%
Theoretical value	0.0620
Implied Volatility	39.43 %
Total Loss Probability	91.94 %
Intrinsic value	0.000000
Present value	0.0620
Break even	109.33 €
Theta	-0.01x
Vega	0.01x
Rho	-0x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company